GlobeNewswire Clinical StudiesOriginal article
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Data ReadoutpositivePermeaDerm®Positive
AI Analysis
Summary
AVITA Medical announced positive PermeaDerm study results showing 70% lower cost than allograft with comparable clinical outcomes and 96% faster preparation time. The data supports the economic and clinical viability of PermeaDerm as an alternative to allograft treatments.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
70% lower product cost than allograft with comparable clinical outcomes and 96% reduction in preparation time
Importance:6/10
Sentiment:
0.75
clinical trialpositive datacost advantagedermatologyallograft comparison
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 18, 2026 11:45 AM